Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Panadeine Extra is a fixed-dose combination analgesic containing 500 mg paracetamol (acetaminophen) and 15 mg codeine phosphate. It is used for the relief of moderate to severe pain, including postoperative dental pain, where non-opioid analgesics alone are insufficient. Paracetamol provides analgesic and antipyretic effects primarily through the central nervous system, likely by inhibiting cyclooxygenase enzymes and modulating central pain pathways. Codeine is an opioid prodrug that is metabolized by the liver enzyme CYP2D6 into morphine, which then acts as an agonist at mu-opioid receptors to inhibit pain signaling. The product is historically associated with GlaxoSmithKline Consumer Healthcare (now Haleon) and has served as a reference comparator in clinical trials evaluating new analgesic combinations, such as those developed by Reckitt Benckiser.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on paracetamol + codeine (GSK).